[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538677":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":34,"responsibleParty":50,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Jordan","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WJMSC","EXPERIMENTAL","\\- Patients receive three intravenous doses of MSCs (1 million\u002Fkg) every two weeks as treatment.",[13],"Biological: WJMSC",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Abdallah Awidi, MD","Cell Therapy Center","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Hanan Jafar, PhD","CONTACT","00962798871087","hanan.jafar@gmail.com",{"name":21,"role":27,"phone":31,"phoneExt":32,"email":33},"0096265355000","23960","abdalla.awidi@gmail.com",[35],{"facility":22,"status":36,"city":37,"state":18,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Amman","00962","Jordan","JO",{"type":42,"coordinates":43},"Point",[44,45],35.94503,31.95522,{"lat":45,"lon":44},[48,49],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},{"name":21,"role":27,"phone":31,"phoneExt":32,"email":33},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Hanan Jafar","Principal investigator","100538677","phase-1-allogeneic-wharton-jelly-mesenchymal-stromal-cell-wjmsc-for-treatment-of-autism-100538677",false,"NCT06293950","Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism","Inclusion Criteria:\n\n* 14 subjects, 4-14 years of age, will be enrolled into this study, who meet the criteria for (ASD\n\nExclusion Criteria:\n\n* Age \\> 14 years.\n* Patient weighing \\\u003C 10 kg.\n* History of severe Allergy\n* History of severe head trauma, defined by loss of consciousness or hospitalization, skull fracture, or stroke.\n* Seizure within the last year before enrollment, or the need for seizure medications either at present or in the past.\n* Evidence or history of severe, moderate, or uncontrolled systemic disease.\n* Inability to follow the prescribed dosing and follow-up schedule.\n* Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 7 days before the initial randomized study period.\n* Subjects taking a selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days before entering the study.\n* History of premature birth \\\u003C35 weeks' gestation.\n* Prior history of stroke in utero or other in utero insult.","ALL","4 Years","14 Years",{"count":64,"type":65},14,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.",[71],"Autism",[73,9],"autism","2025-01-23",{"date":76,"type":77},"2025-01-24","ACTUAL",{"date":79,"type":77},"2022-03-09",{"date":81,"type":65},"2027-12",{"name":5,"class":6},1]